Advancing therapy with iGlarLixi versus premix BIAsp 30 in basal insulin‐treated type 2 diabetes: Design and baseline characteristics of the SoliMix randomized controlled trial-Reference-Cited by-同舟云学术

Advancing therapy with iGlarLixi versus premix BIAsp 30 in basal insulin‐treated type 2 diabetes: Design and baseline characteristics of the SoliMix randomized controlled trial

Published:2021-04-29 Issue:6 Volume:23 Page:1221-1231
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

McCrimmon Rory J.¹^ORCID,Al Sifri Saud²,Emral Rifat³,Mohan Viswanathan⁴^ORCID,Sauque‐Reyna Leobardo⁵,Trescolí Carlos⁶,Lalic Nebojsa⁷,Alvarez Agustina⁸,Demil Nacima⁹,Coudert Mathieu¹⁰,Shaunik Alka¹¹,Bonnemaire Mireille¹²,Rosenstock Julio¹³^ORCID,

Affiliation:

1. Division of Systems Medicine, School of Medicine University of Dundee Dundee UK

2. Al Hada Military Hospital Taif Saudi Arabia

3. Department of Endocrinology and Metabolic Diseases Ankara University Faculty of Medicine Ankara Turkey

4. Dr. Mohan's Diabetes Specialities Centre & Madras Diabetes Research Foundation, IDF Centre of Excellence in Diabetes Care & ICMR Centre for Advanced Research on Diabetes Chennai India

5. Instituto de Diabetes Obesidad y Nutrición S.C. Cuernavaca Mexico

6. Hospital Universitario de La Ribera Alzira Spain

7. Faculty of Medicine of the University of Belgrade, Clinic for Endocrinology, Diabetes and Metabolic Diseases, Clinical Center of Serbia Belgrade Serbia

8. Sanofi Buenos Aires Argentina

9. Diabetes Medical Operation Department Sanofi Chilly‐Mazarin France

10. Biostatistics and Programming Department Sanofi Chilly‐Mazarin France

11. Sanofi US Bridgewater New Jersey USA

12. Sanofi Paris France

13. Dallas Diabetes Research Center at Medical City Dallas Texas USA

Funder

Sanofi

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine